Mylan gets Humira-related IP from AbbVie
AbbVie Inc. licensed Mylan NV non-exclusive rights to patents and intellectual property relating to Humira (adalimumab) in the US and certain other countries (excluding Europe) where AbbVie has IP, which Mylan will use in its development of a Humira biosimilar.
- Large Molecule
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com